Jiangsu Vcare Completes Full Patient Enrollment for Phase II Clinical Trial of VC005 Topical Gel in Mild-to-Moderate Atopic Dermatitis
Published Time:
2025-07-31 18:28
Source:
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the completion of full patient enrollment for its Phase II clinical trial of the self-developed, next-generation highly selective JAK1 inhibitor, VC005 topical gel, for the treatment of mild-to-moderate Atopic Dermatitis (AD). This marks a significant milestone in the VC005 gel development program.
The ongoing study is a multicenter, randomized, double-blind, vehicle-controlled Phase II clinical trial evaluating the efficacy and safety of VC005 gel in adult with mild-to-moderate AD. It aims to assess the gel's efficacy and safety profile in this patient population. The primary efficacy endpoint is the change from baseline in the Eczema Area and Severity Index (EASI) score at Week 8 of treatment.
VC005 gel demonstrated excellent safety and significant efficacy in the completed Phase I clinical study . Concurrently, patient enrollment is actively underway for the Phase III clinical trial of VC005 tablets for the treatment of moderate-to-severe AD.
About VC005
VC005 is a novel, potent, highly selective second-generation JAK1 inhibitor independently developed by Jiangsu Vcare. By selectively inhibiting JAK1, the drug is under clinical development for the treatment of inflammatory and autoimmune diseases such as atopic dermatitis, ankylosing spondylitis, and rheumatoid arthritis. Compared to the currently marketed leading drug Upadacitinib, VC005 exhibits lower JAK2 inhibitory activity (based on in-vitro-kinase-assay results). This profile may potentially mitigate a series of safety concerns associated with excessive JAK2 inhibition in the clinical setting. Furthermore, synergistic efficacy exist between JAK1 and JAK3/TYK2 across multiple diseases. Therefore, while achieving high selectivity for JAK1 versus JAK2, VC005 holds the potential to deliver superior clinical efficacy compared to drugs in its class.
About Atopic Dermatitis (AD)
Atopic Dermatitis (AD) is a chronic, relapsing, inflammatory skin disease characterized primarily by dry skin, intense pruritus (itching), and eczematous rashes, severely impacting patients' quality of life. The global AD patient population is estimated at approximately 230 million. The prevalence of adult AD in China is about 2%–8%, affecting over 70 million people. Among these patients, 67% have mild disease and 33% have moderate-to-severe disease. Frost & Sullivan (F&S) predicts the disease population will continue to grow at a Compound Annual Growth Rate (CAGR) of 1.7% from 2025 to 2030. Traditional therapies, such as corticosteroids, are associated with numerous adverse effects and unlikely to yield long-term advantages, making effective and stable disease control challenging. Topical JAK1 small-molecule targeted inhibitors, belonging to the class of non-corticosteroid immunosuppressants, offer the potential to preserve therapeutic efficacy while further enhancing the medication safety profile for patients with mild-to-moderate AD.
Related News
23
2017
/
08
Jiangsu Vcare Was Honored as Jiangbei New Area Lingque Enterprise
In 2017, the list of “Lingque” enterprises in Jiangbei New District of Nanjing was announced and Jiangsu Vcare Pharmaceutical Technology Co., Ltd. was successfully selected into the list. “Lingque” enterprises project aim to select a group of innovative SMEs with high growth in Jiangbei district and provide the selected enterprises with one-stop support such as equity investment, emergency turnover, loan interest subsidy, R&D subsidies, and etc.. To be successfully selected into the “Lingque” enterprises program is an inspiration to the company. Vcare keep integrating various resources to quickly become bigger and stronger to contribute to the development of Jiangbei New Area.
View Details
15
2017
/
06
Jiangsu Vcare and Yangzhou Princechem Acquired Boya Chemical Company
The signing ceremony of Jiangsu Vcare Pharmaceutical Technology Co., Ltd. and Yangzhou Princechem Co., Ltd. acquiring Boya Chemical (Nantong) Co., Ltd. was held in the conference room of Jiangsu Vcare recently. Boya Chemical (Nantong) Co., Ltd. is located in Yangkou Chemical Industrial Park, Rudong Coastal Economic Development Zone, Jiangsu Province. The company covers an area of 70 acres and is a Hong Kong-owned enterprise. The goal of this acquisition is to build Boya Chemical into a raw material drug manufacturer that meets the standards of China, the United States and the European Union. After renovation, Boya Chemical will be a chemical raw materials production base of Yatai Group and solve the bottleneck problem of Vcare's raw material drug R&D and production. It’s believed that the acquisition will make a significant contribution to Vcare’s production and sales of intermediates and APIs.
View Details
06
2017
/
06
Leaders of Management Committee of Rudong Coastal Economic Development Zone Visited Jiangsu Vcare
Leaders of management committee of Rudong coastal economic development zone visited Jiangsu Vcare on June 1st, 2017. The delegation was received by the vice chairman Jun Qu, general manager Yongqiang Liu, and vice general manager Yanchun Gong of Vcare. The delegation visited the Vcare's chemical research center and drug research center. Mr. Liu introduced R&D progress and advanced equipment to the guests. During the discussion, Mr. Liu introduced the overall development plan of Yatai Group's pharmaceutical industry, and Vcare's development history and the future plan. Mr. Liu also introduced the progress of innovative drug Vicagrel and a series of generic drugs in detail. The leaders of Rudong coastal economic development zone introduced the planning of their park, local investment, environmental protection policies and etc., and expressed their confidence in the research and development prospects of Vcare.
View Details
15
2017
/
05
Leaders of Pukou District Economic and Trade Bureau Visited Jiangsu Vcare
Leaders of Pukou District Economic and Trade Bureau Visited Jiangsu Vcare on May 12, 2017. The general manager Yongqiang Liu received the delegation.
View Details
24
2017
/
04
Jiangsu Vcare Held Mountain Climbing and Tug-of-war Competitions
Jiangsu Vcare organized mountain climbing and tug-of-war activities recently. The mountain climbing competition was divided into men's and women's groups, and each group competed for top three. The venue was located in Laoshan National Forest Park. Everyone climbed the top after efforts. Four teams consisting of Vcare’s two R&D center members conducted a tug-of-war competition after going down the mountain and finally "Lingya team" won the top spot. Everyone had fun.
View Details
30
2017
/
03
Jiangsu Vcare Held the First Quarter Fire Drill
In order to further improve the safety awareness of new employees, Jiangsu Vcare held a fire-fighting exercise on March 30, 2017. New employees had a deeper understanding of fire extinguishers through on-site explanation of the types, inspection methods and instructions of fire extinguishers. Everyone learned about fire-fighting procedures and the use of appliances. The exercise provided a safety guarantee for everyone’s life and work.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn